World News: 10:00 GMT Tuesday 3rd December 2019. [Allied Corp. via Globe Newswire via SPi World News]
KELOWNA, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ("Allied") (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions, stated in it’s October 28 press release that it had entered into a Master Services Agreement with the University of Haifa, Israel via their wholly owned commercialization subsidiary: Carmel - Haifa University Economic Corporation Ltd. (“Carmel-Haifa”). In accordance, Allied has come to a final agreement on the terms for the Research Protocol and associated Pre-Clinical work which is to begin at Haifa University in the Laboratory of Dr. Irit Akarav.
As previously noted, this world-class academic research center gives Allied access to a proprietary pre-clinical animal model that is owned by Carmel-Haifa. This proprietary animal model will focus on specific pharmaceutical cannabinoid research and pharmaceutical product development.
Following approval by the Ministry of Health, Pre-Clinical Phase 1 work will begin. If positive indications are realized in Pre-Clinical Phase 1 it would be followed by Pre-Clinical Phase 2 and Pre-Clinical Phase 3 toward the Research Protocol’s objectives for PTSD indications, safety and efficacy.
Allied now has access to Carmel-Haifa’s leading-edge facilities, proprietary animal model, pharmaceutical development, academic laboratory and associated scientists and investigators, enabling Allied to conduct the pre-clinical phase of the development of a proprietary pharmaceutical product (“AC001”) for which Allied has filed a United States Provisional Patent Application.
This pharmaceutical product targets the treatment of Post-Traumatic Stress Disorder and related mental health conditions. Following the completion of the pre-clinical research phases, Allied intends to bring AC001 through to human clinical trials. After successful completion, Allied would then intend to seek global commercialization.
“We are excited to begin our pre-clinical work with the exceptional team of experienced researchers led by Dr. Irit Akarav at the University of Haifa, Israel,” says David Weinkauf, Chief Development Officer for Allied Corp. “As part of our Intellectual Property and Pharma Development (IP&PD) Strategy, this pre-clinical research allows us to advance the science behind our Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD) and bring help to all those suffering from PTSD.”
Additional information about Allied Corp. can be found at .
Calum Hughes Chief Executive Officer
Additional information about Carmel - Haifa can be found at
Forward-looking statements are based on management’s current expectations and may materially differ from actual results. Further, such forward-looking statements are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Globe Newswire: 10:00 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.